Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

PD-L1

4 articles · Resources: NCBI Gene, OncoKB

Clinical

Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma

Busse C, Hörner M, Saravi B, et al.

Oral and maxillofacial surgery

This retrospective study investigated the spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma (OSCC) by comparing primary tumors and matched lymph node metastases. Findings revealed that both PD-L1 and c-MET were frequently expressed in primary tumors but at significantly lower levels in corresponding lymph node metastases. A substantial discordance in PD-L1 CPS status was observed between the two tumor compartments, potentially impacting biomarker classification. While higher PD-L1 expression in primary tumors was associated with nodal metastasis, no significant correlation was found between PD-L1 and c-MET. These results highlight the critical role of spatial heterogeneity in biomarker assessment for OSCC.

Clinical · Molecular biology · Bioinfo & AI

Identification of PD-1-Related Genes as Prognostic Biomarkers in Lung Adenocarcinoma

Jia B, Gong T, Chen C, et al.

Human mutation

This study developed a robust prognostic model for lung adenocarcinoma (LUAD) by focusing on PD-1-related genes. Utilizing advanced bioinformatics analyses and in vitro validations, a nine-gene risk model (ADA2, CD53, HLA-DMA, ITGAX, MYO1F, NCKAP1L, PTPRC, RENBP, TNFAIP8L2) was constructed. This model demonstrated strong predictive performance, stratifying patients into high- and low-risk groups with distinct prognoses. High-risk patients exhibited a worse prognosis and lower immune infiltration, while drug sensitivity analyses identified specific candidate therapeutic agents for each group.

Molecular biology · Bioinfo & AI

ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma

Chen W, Li H, Zeng J, et al.

PeerJ

This study identifies ERO1A as a novel and promising biomarker for early-stage lung adenocarcinoma (esLUAD). High ERO1A expression is associated with poor prognosis, yet paradoxically, it correlates with an immune-activated tumor microenvironment. Tumors with elevated ERO1A levels demonstrate a superior response to immune checkpoint inhibitors. This biomarker could therefore aid in patient stratification and guide peri-operative therapeutic decisions.

Clinical · Molecular biology

Biomarker study of pembrolizumab in patients with advanced rare cancers

Naing A, Li X, Wang Q, et al.

Cell reports. Medicine

This phase 2 study investigated the efficacy of pembrolizumab in 154 patients with advanced rare cancers, conditions often lacking established treatment options. The findings demonstrated an objective response rate of 14.8% and a clinical benefit rate of 26.8%. Multi-modal analysis revealed an association between clinical benefit and biomarkers such as high microsatellite instability (MSI-H), high tumor mutation burden (TMB-H), and a PD-L1 combined positive score (CPS) ≥10. The study also highlighted features of the tumor immune microenvironment, such as increased immune infiltration and T cell activation prior to treatment, as potential predictive markers.